Janssen Pharmaceutical Cos.
www.janssen.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Janssen Pharmaceutical Cos.
Comirnaty mRNA Vaccine First To Get EU Clearance For Under-12s
The EMA is going all out to maximize coverage of the EU population with both vaccines and treatments for COVID-19.
Coronavirus Notebook: Molnupiravir EU Approval Likely By Year End, Special CHMP Session Due On Comirnaty in 5 to 11-year-olds
The EMA is assessing the Janssen vaccine as a booster, and Switzerland is evaluating the use of the Pfizer/BioNTech and Moderna COVID-19 vaccines in younger age groups. The WHO has announced the first voluntary global license on a COVID-19 antibody detection technology.
ViiV & Janssen Win English Funding First For HIV Therapy
Around 13,000 people are now expected to be eligible for treatment with the long-acting, injectable Vocabria/Rekambys combination therapy in England.
Earlier R&D Programs, Maturing Candidates Emerge From Bristol’s Pipeline
BMS is advancing a growing Phase I and II R&D pipeline, including a Factor XIa inhibitor with lower bleeding risk than current anticoagulants, as well as other internal and external research programs.
Company Information
- Industry
- Pharmaceuticals